Diabetes Patients

Source: www.ncbi.nlm.nih.gov --- 3 days ago
Related Articles Metabolic Syndrome Predicts New Onset Of Chronic Kidney Disease In 5829 Patients with Type 2 Diabetes - A 5-year Prospective Analysis of the Hong Kong Diabetes Registry. Diabetes Care. 2008 Oct 3; Authors: Luk AO, So WY, Ma RC, Kong AP, Ozaki R, Ng VS, Yu LW, Lau WW, Yang X, Chow FC, Chan JC, Tong PC Objective: Type 2 Diabetes is the leading cause of end stage renal disease worldwide. Aside from hyperglycemia and hypertension, other metabolic factors may determine renal outcome. We examined risk associations of metabolic syndrome (MetS) with new onset of chronic kidney disease (CKD) in 5829 Chinese Patients with type 2 Diabetes enrolled between 1995 and 2005. Method: MetS was defined by National Cholesterol Education Program's Adult Treatment Panel III with Asian definition of obesity. Estimated glomerular filtration rate (eGFR) was calculated using abbreviated Modification of Diet in Renal Disease formula modified for Chinese population. New onset of CKD was defined as estimated eGFR < 60 ml/min/1.73m(2) at the time of censor. Subjects with CKD at baseline were excluded from the analysis. Results: After a median follow-up duration of 4.6 years [inter-quartile range: 1.9 - 7.3 years], 741 Patients developed CKD. The multivariable-adjusted hazard ratio of CKD was 1.31, 95% confidence interval [CI] 1.12 - 1.54, p=0.001 for subjects with MetS compared to without. Relative to subjects with no other components of MetS exce ...

Source: www.ncbi.nlm.nih.gov --- 5 days ago
Related Articles Improvement of glycaemic and lipid profiles with muraglitazar plus metformin in Patients with type 2 Diabetes: an active-control trial with glimepiride. Diab Vasc Dis Res. 2008 Sep;5(3):168-76 Authors: Rubin CJ, Ledeine JM, Fiedorek FT The efficacy and safety of muraglitazar versus glimepiride were evaluated in Patients with type 2 Diabetes. After open-label metformin monotherapy, 1,805 Patients received randomised therapy with muraglitazar 2.5 mg or 5 mg or with glimepiride 1 mg in a double-blind 52-week study. The primary end point was change in glycosylated haemoglobin (HbA1C); secondary end points were changes in fasting lipid levels and glycaemic indices. At week 52, the reduction in HbA1C with muraglitazar 5 mg plus metformin was superior (p<0.0001) and with muraglitazar 2.5 mg it was non-inferior in comparison with glimepiride. At week 12, muraglitazar significantly decreased triglyceride levels (p<0.0001) and increased levels of high-density lipoprotein cholesterol (HDL-C) (p<0.0001). Oedema, weight gain and heart failure were more evident with muraglitazar. Muraglitazar 5 mg plus metformin significantly improved HbA1C, triglyceride and HDL-C levels in Patients with type 2 Diabetes. Cardiovascular events were similar among groups (~2%), but there was an imbalance of total mortality in favour of glimepiride. PMID: 18777489 [PubMed - indexed for MEDLINE] ...

Source: www.ncbi.nlm.nih.gov --- 1 day ago
[The effect of short-time continuous positive airway pressure treatment on insulin sensitivity in Patients with obstructive sleep apnea-hypopnea syndrome and type 2 Diabetes] Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2008 Jul;22(13):597-9 Authors: Wang H, Wang L, Liu J OBJECTIVE: To investigate the effects of short-time continuous positive airway pressure treatment before the surgery on insulin sensitivity in Patients with obstructive sleep apnea-hypopnea syndrome and type 2 Diabetes who need the operation of uvulopalatophargngoplasty. METHOD: Thirty cases of Patients with moderate and severe obstructive sleep apnea-hypopnea syndrome and type 2 Diabetes who need the operation of UPPP were included in this study. The apnea hypopnea index (AHI) and LSaO2 and the insulin sensitivity index (ISI) was evaluated by homeostasis model assessment (HOMA), after 7 days of effective CPAP treatment. Subsequently, the data of the PSG and the ISI were rechecked and compared to the data previously achieved. RESULT: After 7 days of effective CPAP treatment, the level of AHI and LSaO2 changed (P < 0.05). The level of ISI improved (P < 0.05), while the level of AHI was correlated with fasting blood insulin level (r = 0.6365, P < 0.05) and was inverse correlated with insulin sensitivity (r = - 0.6229, P < 0.05). There was an negative correlation between LSaO2 and fasting blood insulin level (r = -0.8889, P < 0.05), and there was a correlation between ...

Source: www.ncbi.nlm.nih.gov --- 2 days ago
Related Articles Effect of exenatide on 24-hour blood glucose profile compared with placebo in Patients with type 2 Diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study. Clin Ther. 2008 May;30(5):858-67 Authors: Schwartz SL, Ratner RE, Kim DD, Qu Y, Fechner LL, Lenox SM, Holcombe JH OBJECTIVE: The aim of this study was to examine the glucose-lowering effect of exenatide over 24 hours in Patients with type 2 Diabetes with inadequate glycemic control using metformin, with or without a thiazolidinedione (TZD). METHODS: This randomized, double-blind, 2-arm, parallel-group, placebo-controlled, 2-week study was conducted in Patients with type 2 Diabetes with inadequate glycemic control, despite metformin with or without a TZD. Patients underwent a baseline and a week-2 (study end) 24-hour admission during which serial serum glucose measurements were taken. Preprandial and postprandial concentrations of triglycerides and free fatty acids were also measured. Meals provided for each patient were identical at the baseline and week-2 assessments. Following the baseline admission, Patients were randomized to receive SC injections of either exenatide (5 microg BID for 1 week, then 10 microg BID for the next week) or placebo (volume equivalent) for 14 days. RESULTS: A total of 30 Patients (19 women [63%], 11 men [37%]; mean [SD] age, 52.6 [11.2] years; weight, 94.3 [23.0] kg; body mass index, 34.2 [6.1] kg/ ...

Source: www.moreover.com --- 38 days ago
Description Recent years have seen a sharp rise in the incidence of Type 2 Diabetes, also called non-insulin dependent Diabetes, and the serious complications that often result. ...

Source: www.moreover.com --- 2 days ago
Nassaji-Zavareh et al. - Herpes Zoster (HZ) is reactivation of latent varicella-zoster virus that involves dermatomes. Aging and immunosupressed states are among the main risk factors. ...

Source: www.ncbi.nlm.nih.gov --- 7 days ago
Related Articles Rapamycin monotherapy in Patients with type 1 Diabetes modifies CD4+CD25+FOXP3+ regulatory T-cells. Diabetes. 2008 Sep;57(9):2341-7 Authors: Monti P, Scirpoli M, Maffi P, Piemonti L, Secchi A, Bonifacio E, Roncarolo MG, Battaglia M OBJECTIVE: Rapamycin is an immunosuppressive drug currently used to prevent graft rejection in humans, which is considered permissive for tolerance induction. Rapamycin allows expansion of both murine and human naturally occurring CD4(+)CD25(+)FOXP3(+) T regulatory cells (nTregs), which are pivotal for the induction and maintenance of peripheral tolerance. Preclinical murine models have shown that rapamycin enhances nTreg proliferation and regulatory function also in vivo. Objective of this study was to assess whether rapamycin has in vivo effects on human nTregs. RESEARCH DESIGN AND METHODS: nTreg numbers and function were examined in a unique set of Patients with type 1 Diabetes who underwent rapamycin monotherapy before islet transplantation. RESULTS: We found that rapamycin monotherapy did not alter the frequency and functional features, namely proliferation and cytokine production, of circulating nTregs. However, nTregs isolated from type 1 diabetic Patients under rapamycin treatment had an increased capability to suppress proliferation of CD4(+)CD25(-) effector T-cells compared with that before treatment. CONCLUSIONS: These findings demonstrate that rapamycin directly affects human nTr ...

Source: www.ncbi.nlm.nih.gov --- 38 days ago
Related Articles Drug eluting stents in Patients with Diabetes. BMJ. 2008;337:a1359 Authors: Agostoni P, Branden FV PMID: 18757997 [PubMed - as supplied by publisher] ...

Source: www.ncbi.nlm.nih.gov --- 30 days ago
Related Articles High molecular weight adiponectin correlates positively with myeloperoxidase in Patients with type 2 Diabetes mellitus. Diabetes Res Clin Pract. 2008 Sep 6; Authors: Bobbert P, Rauch U, Stratmann B, Goldin-Lang P, Antoniak S, Bobbert T, Schultheiss HP, Tschoepe D Adiponectin (APN) is present in human plasma as a low molecular weight (LMW), a middle molecular weight (MMW) and a high molecular weight form (HMW). As a support to determine properties such as anti-atherogenic or atherogenic effects, recent clinical studies suppose to determine the ratio of each APN multimer to total APN but not the absolute plasma concentration of APN. In the present study, the correlation of APN and its multimers with myeloperoxidase (MPO), an enzyme with pro-inflammatory properties, was examined in Patients with type 2 Diabetes mellitus. MPO and APN serum levels were assessed in 49 Patients with type 2 Diabetes mellitus at the beginning and at the end of an anti-diabetic treatment. After treatment a significant increase in the ratio of HMW to total APN (from 0.43+/-0.16 to 0.59+/-0.14, p<0.05) was found. Before treatment, HMW-APN was correlated positively with MPO (r=0.314, p<0.05). Moreover, a positive correlation was observed between the increased HMW ratio and MPO during treatment (r=0.304, p<0.05). HMW-APN correlates positively with MPO in Patients with type 2 Diabetes. Therefore, HMW-APN may exert possible pro-inflammatory effects i ...

Source: www.ncbi.nlm.nih.gov --- 30 days ago
Related Articles Changes in adiponectin multimer distribution in response to atorvastatin treatment in Patients with type 2 Diabetes. Clin Endocrinol (Oxf). 2008 Sep 5; Authors: von Eynatten M, Liu D, Bluemm A, Schuster T, Baumann M, Lutz J, Heemann U, Dugi K, Nawroth P, Bierhaus A, Humpert P Objective: Multimeric high molecular weight (HMW) forms of adiponectin were previously shown to be inversely associated with the extent of atherosclerosis in males and are downregulated in Patients with the metabolic syndrome and type 2 Diabetes. In this study, potential influences of atorvastatin therapy on adiponectin multimer distribution were studied in Patients with type 2 Diabetes. Design, Patients and measurements: The effect of 40mg atorvastatin on HMW, medium molecular weight (MMW), and low molecular weight (LMW) isoforms of adiponectin were investigated in 75 Patients (23 females; 52 males) with type 2 Diabetes in an 8-week-long, placebo-controlled and randomized study. Adiponectin multimeric isoforms were detected by western blot analysis. Results: After atorvastatin therapy the median serum concentration of HMW adiponectin increased significantly by 42.3% (1.68 vs. 2.39 mug/ml; p<0.001), while concentrations of MMW adiponectin and LMW adiponectin significantly decreased by 20.8% and 23.2%, respectively (MMW: 3.31 vs. 2.62 mug/ml, p=0.047; LMW: 0.56 vs. 0.43 mug/ml, p=0.033). Median total adiponectin levels were not significantly alter ...

Source: www.moreover.com --- 32 days ago
Extract not available. ...

Source: www.moreover.com --- 31 days ago
ROME, Sept. 9 /CNW/ - << - Exciting New Data From the FIELD Study Show Additional Microvascular-Associated Benefits of Fenofibrate - The First Time in a Large-Scale Prospective Study That any Lipid-Modifying Therapy has Been Shown to Significantly ...

Source: www.ncbi.nlm.nih.gov --- 37 days ago
Related Articles Intensive insulin therapy in Patients with type 2 Diabetes. Lancet. 2008 Aug 30;372(9640):717; author reply 717-8 Authors: DeVries JH, Siegelaar S, Holleman F, Hoekstra JB PMID: 18761219 [PubMed - in process] ...

Source: www.moreover.com --- 31 days ago
SAN JUAN CAPISTRANO, Calif. ...

Source: www.ncbi.nlm.nih.gov --- 37 days ago
Related Articles Intensive insulin therapy in Patients with type 2 Diabetes - Authors' reply. Lancet. 2008 Aug 30;372(9640):717-718 Authors: Xu W, Zeng L, Li Y, Li M, Weng J PMID: 18761220 [PubMed - as supplied by publisher] ...

Source: www.ncbi.nlm.nih.gov --- 27 days ago
Related Articles Recurrence of cardiovascular events in Patients with type 2 Diabetes: epidemiology and risk factors. Diabetes Care. 2008 Sep 9; Authors: Giorda CB, Avogaro A, Maggini M, Lombardo F, Mannucci E, Turco S, Alegiani SS, Raschetti R, Velussi M, Ferrannini E, Objective: To assess incidence and risk factors for recurrent cardiovascular disease (CVD) in Type 2 Diabetes mellitus (T2DM) Research Design and Methods- We estimated the incidence of recurrent cardiovascular events in T2DM Patients, aged 40-97 years, followed by a network of Diabetes clinics. The analysis was conducted separately for 2,788 Patients with CVD at enrolment (cohort A) and for 844 Patients developing the first episode during the observation period (cohort B). Results - During 4 years of follow up, in cohort A the age-adjusted incidence of recurrent event (per 1,000 person-years) was 72.7 (95% C.I. 58.3-87.1) in men and 32.5 (95% C.I. 21.2-43.7) in women, whereas in cohort B it was 40.1 (95% C.I. 17.4-62.9) in men and 22.4 (95% C.I. 12.9 - 32.0) in women. After controlling for potential predictors (familial CVD, obesity, smoking, Diabetes duration, glycaemic control, microvascular complications, geographic area, anti-hypertensive and lipid-lowering treatment), male gender, older age and insulin use were significant, independent risk predictors (cohort A); serum triglyceride levels >/=1.69 mmom/l emerged as the only metabolic (negative) prognostic factor (co ...

Source: www.bellaonline.com --- 16 days ago
Medical research confirms that people with thyroid diseases, are at higher risk for developing Type II Diabetes, also called Adult Onset Diabetes. This article gives four pointers for avoiding the onset of this serious endocrine disease, that is common to thyroid Patients. ...

Source: www.ctv.ca --- 7 days ago
Studies show that depression can exacerbate a number of chronic illnesses and scientists have now found that depression in elderly diabetics can increase their risk of death. ...

Source: www.medicalnewstoday.com --- 21 days ago
UroToday.com - Although it has been known for two decades that males with type 2 Diabetes have low testosterone concentrations and that subjects with low testosterone concentrations are likely to develop type 2 Diabetes, the issue of low testosterone concentrations has been treated as a marker associated with type 2 Diabetes and features of the metabolic syndrome(1-3). These studies were based on total testosterone concentrations. ...

Source: www.moreover.com --- 39 days ago
MedWire News Sep 1 2008 4:49PM GMT ...